Flexible fiberoptic bronchoscopy and remifentanil target-controlled infusion in ICU: a preliminary study

Ludivine Chalumeau-Lemoine1, Annabelle Stoclin, Valérie Billard

  • 1Service de Réanimation médico-chirurgicale, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805, Villejuif, France. ludivine.CHALUMEAU-LEMOINE@igr.fr

Intensive Care Medicine
|October 12, 2012
PubMed
Abstract

Insights

Sedation with remifentanil target-controlled infusion (Remi-TCI) safely and effectively supports flexible fiberoptic bronchoscopy (FFB) in critically ill patients. This approach improved patient comfort and procedure conditions during FFB in the ICU.

Area of Science:

  • Critical Care Medicine
  • Anesthesiology
  • Pulmonology

Background:

  • Flexible fiberoptic bronchoscopy (FFB) is a vital diagnostic tool in intensive care units (ICUs).
  • FFB can cause patient discomfort, pain, and compromise respiratory/hemodynamic stability in critically ill individuals.
  • Remifentanil, an ultrashort-acting opioid, offers effective sedation for painful procedures in spontaneously breathing patients.

Purpose of the Study:

  • To evaluate the safety and efficacy of remifentanil target-controlled infusion (Remi-TCI) for sedating patients undergoing FFB.
  • To assess Remi-TCI's impact on critically ill patients with spontaneous ventilation during FFB in the ICU.

Main Methods:

  • A monocentric prospective study involving fourteen patients undergoing FFB.
  • Remifentanil target-controlled infusion (Remi-TCI) was administered, with initial concentrations titrated based on patient comfort and sedation levels.
  • Respiratory, hemodynamic, comfort, sedation, FFB conditions, and recovery parameters were monitored before, during, and after the procedure.

Main Results:

  • FFB was successfully completed in all patients with good sedation, comfort, and cough control.
  • No severe respiratory or hemodynamic complications were observed during the FFB procedures.
  • Patients reported low pain levels and high satisfaction, with maximum remifentanil concentrations averaging 2.5 ng/mL.

Conclusions:

  • Sedation with Remi-TCI appears safe and effective for critically ill, spontaneously ventilating patients undergoing FFB.
  • These findings suggest potential for broader application of Remi-TCI in managing uncomfortable or painful procedures within the ICU setting.